The diagnosis and treatment of whipple’s disease
- 45 Downloads
Whipple’s disease is a rare, chronic, and systemic infectious disease caused by the ubiquitously occuring bacterium Tropheryma whippelii. For two reasons, the disease represents a good example for documenting the input of modern molecular-based techniques into pathogenetic, diagnostic, and therapeutic concepts in clinical medicine. First, the unidentified and uncultivable causative organism has been characterized by novel molecular-genetic techniques. Second, in contrast to other chronic inflammatory disorders, clinical manifestations of T. whippelii infection seem to be based on reduced T-cell helper type 1 (TH1) activity. These findings have led to an improved pathophysiologic understanding of the disease and to new aspects in treatment strategies that are discussed in this paper.
Unable to display preview. Download preview PDF.
References and Recommended Reading
- 1.Dobbins WO III: Whipple’s DiseaseIn. Springfield, IL: Charles C Thomas; 1987.Google Scholar
- 2.Marth T: Whipple’s disease. In Principles and Practice of Infectious Disease, edn. 5. Edited by Mandell GL, Dolin R, Bennett JE.Philadelphia: Churchill Livingstone; 1999: 1170–1174.Google Scholar
- 3.Feurle GE, Marth T: An evaluation of antimicrobial treatment for Whipple’s disease—tetracycline versus trimethoprim-sulfamethoxazole. Dig Dis Sci 1994, 39:1642–1648.A large retrospective therapy study emphasizing the superior role of trimethoprim-sulfamethoxazole over tetracycline in the primary treatment of Whipple’s disease and the treatment of relapse.PubMedCrossRefGoogle Scholar
- 9.Rosenblatt HM: Immunodeficiencies associated with medical therapy. In Handbook of Mucosal Immunology. Edited by Ogra PL,McGhee JR, Mestecky J, et al. San Diego: Academic Press;1994:824–835.Google Scholar
- 13.Relman DA, Schmidt TM, Macdermott RP, Falkow S: Identification of the uncultured bacillus of Whipple’s disease. New Engl J Med 1992, 327:293–301.phylogenetic classification of the up to the year 2000 uncultivable causative bacterium as an actinomycetes based on analysis of the bacterial 16rRNA with the use of broad range and specific primers. Based on this work, specific detection of T. whippelii in specimens by PCR became available.PubMedCrossRefGoogle Scholar
- 14.Ramzan NN, Loftus E, Burgart LJ, et al.: Diagnosis and monitoring of Whipple’s disease by polymerase chain reaction. Ann Intern Med 1997, 126:520–527.Describes the use of PCR in a larger group to diagnose and monitor Whipple’s disease in gastrointetstinal and cerebrospinal fluid specimens and compares it with conventional histopathological diagnosis.PubMedGoogle Scholar
- 27.Raoult D, Birg ML, La Scola B, et al.: Cultivation of the bacillus of Whipple’s disease. N Engl J Med 2000, 342:620–625.The first successful growth and propagation of T. whippelii in vitro with the use of special centrifuge and cell culture techniques. In this paper, the first polyclonal antibodies also have been generated; ie, IgM antibodies show specific reactivity to sera/tissue of Whipple’s disease patients, and IgG antibodies react to sera of many healthy subjects.PubMedCrossRefGoogle Scholar
- 29.Marth T, Neurath M, Cuccherini BA, Strober W: Defects of monocyte interleukin-12 production and humoral immunity in Whipple’s disease. Gastroenterology 1997, 113:442–448.Shows that an impaired function of antigen-presenting cells in Whipple’s disease may be related to a reduced macrophage IL-12 production with secondary impaired cell-mediated immune responses including IFN-g secretion and decreased IgG2 subclass levels.PubMedCrossRefGoogle Scholar
- 33.Feurle GE, Volk B, Waldherr R: Cerebral Whipple’s disease with negative jejunal histology. N Engl J Med 1979, 300:907–908.Points to the protean nature of the disorder in that the dangerous and in many cases progressive CNS manifestations may occur in the absence of "typical" clinical Whipple’s disease features.PubMedCrossRefGoogle Scholar